- |||||||||| triamcinolone acetonide topical / Generic mfg.
Trial completion date, Trial primary completion date: Fractional Ablative Laser Treatment for Skin Grafts (clinicaltrials.gov) - Jan 26, 2023
P=N/A, N=29, Recruiting,
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2023 --> Apr 2023
- |||||||||| Trial completion date: Hormonal Mechanisms of Sleep Restriction - Axis Study (clinicaltrials.gov) - Jan 26, 2023
P1, N=80, Active, not recruiting,
Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2023 --> Apr 2023 Trial completion date: Dec 2022 --> Dec 2023
- |||||||||| lenalidomide / Generic mfg., clarithromycin / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: BiRd vs Rd: BiRd vs. Rd as Initial Therapy in Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2023
P3, N=12, Terminated,
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Aug 2024 --> Jul 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Jun 2022; low enrollment
- |||||||||| Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: ClaSPd: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (clinicaltrials.gov) - Jan 26, 2023
P2, N=4, Terminated,
Trial completion date: Aug 2024 --> Jul 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Jun 2022; low enrollment N=26 --> 4 | Trial completion date: Nov 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Nov 2022; low enrollment
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Enrollment change, Trial termination: PROUD Study - Preventing Opioid Use Disorders (clinicaltrials.gov) - Jan 26, 2023
P4, N=7, Terminated,
N=26 --> 4 | Trial completion date: Nov 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Nov 2022; low enrollment N=170 --> 7 | Recruiting --> Terminated; Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Enrollment change: MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs (clinicaltrials.gov) - Jan 26, 2023
P2, N=17, Active, not recruiting,
N=170 --> 7 | Recruiting --> Terminated; Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned. Recruiting --> Active, not recruiting | N=84 --> 17
- |||||||||| Campath (alemtuzumab) / Sanofi, Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - Jan 26, 2023
P2, N=18, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Rheumatoid Meningitis in a patient with Overlap Syndrome: the usefulness of ACPA determination in CSF. (Pubmed Central) - Jan 26, 2023
We diagnosed RM and started methylprednisolone IV mg/kg once daily...ACPA levels in CSF could be a relevant diagnostic clue in the setting of central nervous system (CNS) disturbance and overlapping autoimmune conditions that include RA. In our case, the presence of a suggestive clinical scenario of RM reinforces the probable pathogenic role of ACPA when it is present in the CNS, even without intrathecal synthesis evidence.
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Preclinical, Journal: In Vitro Drug Delivery of a Fixed-Dose Combination of Fluticasone Furoate/Umeclidinium/Vilanterol from a Dry Powder Inhaler. (Pubmed Central) - Jan 26, 2023
Dose delivery assessments across all flow rates and inhalation profiles indicate that patients with all severity levels of COPD or asthma can achieve the required inspiratory effort for efficient delivery of all components of FF/UMEC/VI from the ELLIPTA DPI. Dose emission profiles suggest rapid and near-complete dose delivery from the ELLIPTA DPI before reaching PIF.
- |||||||||| hydrocortisone / Generic mfg.
Journal, Checkpoint inhibition: Immune checkpoint inhibitor-mediated hypophysitis: no place like home. (Pubmed Central) - Jan 26, 2023
In the absence of severe features (sodium <125 mmol/L, hypotension, reduced consciousness, hypoglycaemia and/or visual field defect), patients were administered a single intravenous dose of hydrocortisone (100 mg), observed for at least 4 h and then discharged on oral hydrocortisone (20 mg, 10 mg and 10 mg)...There were no 30-day readmissions or any associated hypophysitis-related mortality. All patients continued ICI therapy without interruption.
- |||||||||| cyclophosphamide / Generic mfg., mycophenolate mofetil / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Journal: A case of antisynthetase syndrome presenting solely with life-threatening interstitial lung disease. (Pubmed Central) - Jan 26, 2023
He was diagnosed with amyopathic antisynthetase syndrome - frequently considered as a form of idiopathic inflammatory myopathy (IIM) - and treated with further intravenous methylprednisolone and cyclophosphamide. Oxygen therapy was gradually weaned and the patient discharged on mycophenolate mofetil and a weaning course of oral steroids.
- |||||||||| dexamethasone / Generic mfg., ibuprofen / Generic mfg.
Journal: Anti-inflammatory Therapy Protects Spiral Ganglion Neurons After Aminoglycoside Antibiotic-Induced Hair Cell Loss. (Pubmed Central) - Jan 26, 2023
Efficacy of ibuprofen treatment was augmented by co-administration of the nicotinamide adenine dinucleotide-stabilizing agent P7C3-A20. Our results support a critical role of neuroinflammation in SGN degeneration after aminoglycoside antibiotic-mediated cochlear hair cell loss, as well as a neuroprotective strategy that could improve cochlear implant efficacy.
- |||||||||| dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: Duration of Analgesia in Bier Block for Patients Undergoing Hand Surgery (clinicaltrials.gov) - Jan 25, 2023
P=N/A, N=75, Not yet recruiting,
Our results support a critical role of neuroinflammation in SGN degeneration after aminoglycoside antibiotic-mediated cochlear hair cell loss, as well as a neuroprotective strategy that could improve cochlear implant efficacy. Trial completion date: Dec 2025 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
- |||||||||| dexamethasone / Generic mfg., clonidine / Generic mfg., epinephrine / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: RCT Comparing ESPB Solutions in Breast Surgery (clinicaltrials.gov) - Jan 25, 2023
P2, N=75, Recruiting,
Trial completion date: Dec 2025 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024 Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- |||||||||| bortezomib / Generic mfg., pomalidomide / Generic mfg.
Trial completion date, Trial primary completion date: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD (clinicaltrials.gov) - Jan 25, 2023
P1, N=36, Active, not recruiting,
Trial completion date: Dec 2030 --> Jun 2023 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Enrollment open, Trial completion date, Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world: To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (clinicaltrials.gov) - Jan 25, 2023
P4, N=460, Recruiting,
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023
- |||||||||| Darzalex (daratumumab) / J&J
Enrollment open, Trial completion date: CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov) - Jan 25, 2023
P1, N=20, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023 Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Apr 2026
- |||||||||| piperacillin sodium/tazobactam sodium / Generic mfg., epinephrine / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
AN EXTREME CASE OF TONGUE SWELLING: LUDWIG ANGINA IN AN ADOLESCENT FEMALE WITH IRAK-4 DEFICIENCY () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2234;
Ludwig’s angina and angioedema can present similarly, and there have been multiple cases of patients with IRAK-4 deficiency to have concomitant IgA deficiency. It is imperative to consider an infectious etiology in the setting of facial swelling and airway obstruction for prompt antibiotic treatment in patients with IRAK-4 deficiency.
- |||||||||| hydrocortisone / Generic mfg.
ABRUPT DISCONTINUATION VERSUS WEANING OF HYDROCORTISONE IN THE TREATMENT OF REFRACTORY SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2218;
It is imperative to consider an infectious etiology in the setting of facial swelling and airway obstruction for prompt antibiotic treatment in patients with IRAK-4 deficiency. Among adults treated with HCT for septic shock, there was no difference in rates of recurrent shock when comparing a weaning strategy to an abrupt discontinuation strategy.
- |||||||||| hydrocortisone / Generic mfg.
HYDROCORTISONE VERSUS VASOPRESSIN FOR THE MANAGEMENT OF SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2217;
Among adults treated with HCT for septic shock, there was no difference in rates of recurrent shock when comparing a weaning strategy to an abrupt discontinuation strategy. Addition of hydrocortisone to norepinephrine was associated with a lower 28-day mortality in patients with septic shock compared to addition of vasopressin.
- |||||||||| midodrine hydrochloride / Generic mfg.
EFFECT OF MIDODRINE ON LENGTH OF STAY IN ADULT PATIENTS WITH SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2216;
Patients receiving midodrine had higher use of RRT, two or more vasopressors, and IV hydrocortisone. Use of midodrine in adults with septic shock was associated with longer hospital LOS and a higher 30-day readmission rate.
- |||||||||| hydrocortisone / Generic mfg.
EFFECT OF HYDROCORTISONE ON OUTCOMES IN IMMUNOCOMPROMISED PATIENTS WITH SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2215;
Use of midodrine in adults with septic shock was associated with longer hospital LOS and a higher 30-day readmission rate. There were no significant differences in outcomes between immunocompromised and immunocompetent patients who received hydrocortisone for septic shock.Further studies on long-term outcomes and stratified on source of septic shock our type of immunosuppression may be further illuminating.
- |||||||||| hydrocortisone / Generic mfg.
VARIABLE DOSING STRATEGIES OF HYDROCORTISONE IN INTENSIVE CARE UNIT SEPTIC SHOCK PATIENTS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2187;
There were no significant differences in outcomes between immunocompromised and immunocompetent patients who received hydrocortisone for septic shock.Further studies on long-term outcomes and stratified on source of septic shock our type of immunosuppression may be further illuminating. Hydrocortisone 100 mg every 8 hrs dosing strategy may lead to earlier vasopressor discontinuation rates and warrants further evaluation.
- |||||||||| Bridion (sugammadex) / Merck (MSD)
ANAPHYLACTIC REACTION AFTER SUGAMMADEX ADMINISTRATION () - Jan 25, 2023 - Abstract #SCCM2023SCCM_2144;
Description: A 44 year-old male with a past medical history significant for traumatic brain injury (TBI) and cerebral palsy presented with skin changes around his baclofen pump...For presumed anaphylactic reaction, the patient was given 100mg of hydrocortisone and further doses of epinephrine...While NBMA-associated anaphylaxis is commonly peri-intubation and sugammadex reactions are typically peri-extubation, patients can also be allergic to the sugammadex-rocuronium complex, further complicating attempts to distinguish between the two for future avoidance. As research is devoted towards understanding sugammadex anaphylaxis and possible alternative approaches, providers will have more information for determining the risks and benefits of different anesthetic methods in patients.
- |||||||||| dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
LATE (≥ 7 DAYS) SYSTEMIC POSTNATAL CORTICOSTEROIDS FOR BRONCHOPULMONARY DYSPLASIA: A META-ANALYSIS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1966;
The use of late systemic corticosteroids is shown to have significantly reduced the mortality in preterm infants, but had no significant effect on the incidence of BPD. More RCTs with longer follow-ups addressing the appropriate dose and timing of steroid therapy are needed.
- |||||||||| Mycamine (micafungin) / Astellas
AN ELUSIVE AND DEADLY PRESENTATION OF TRACHEOBRONCHIAL ASPERGILLOSIS COINFECTION IN COVID-19 () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1908;
She was treated for DKA and started on Remdesivir and Dexamethasone for COVID-19 infection...After resuscitation, her beta-glucan was 364 pg/ml and Micafungin was started...The high peak pressures on the ventilator prompted further investigation by bronchoscopy that uncovered her aspergillus infection. Considering the high mortality rate of TBA, our case shows high level of suspicion and thorough workup is needed for its diagnosis.
- |||||||||| dexamethasone / Generic mfg., methotrexate / Generic mfg.
A REPORT OF DISSEMINATED HISTOPLASMOSIS IN AN IMMUNOCOMPROMISED PATIENT FOLLOWING COVID-19 INFECTION () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1900;
It is important to be aware of the impact that the COVID-19 pandemic has on the emergence of infectious disease and the role its treatment plays in immune suppression. Disseminated histoplasmosis is a consideration for immunocompromised patients in high risk, H. capsulatum endemic areas who are being treated for COVID-19 with high doses of steroids for prolonged periods.
- |||||||||| hydrocortisone / Generic mfg.
EVALUATION OF STRESS-DOSE CORTICOSTEROID TAPER VERSUS ABRUPT CESSATION IN SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1821;
There was no difference in rebound shock in critically ill septic shock patients that received different stress dose corticosteroid discontinuation strategies. The taper strategy was associated with longer durations of ICU stay, hospital stay, septic shock, and hydrocortisone use at our institution.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB-INDUCED MYOCARDITIS WITH CONCOMITANT MYOSITIS AND HEPATITIS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1764;
Clinicians caring for patients who receive ICIs should be vigilant about the broad toxicity profile of these agents, as early recognition and expert consultation is pivotal to avoid morbidity and mortality. If appropriate clinical response is not achieved with corticosteroids alone, additional immunomodulatory medications such as IVIg can be considered.
- |||||||||| hydrocortisone / Generic mfg.
OUTCOMES AND TIMING OF STRESS-DOSE HYDROCORTISONE IN PEDIATRIC SEPTIC SHOCK () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1730;
Preliminary data suggests there is an increased VIS at 48 hours, increased PICU and hospital LOS, and decreased VFD with early administration of HCT. Although PIM-3 scores were higher in the early group, mortality was similar between groups.
- |||||||||| hydrocortisone / Generic mfg., enoxaparin sodium / Generic mfg.
BILATERAL CEREBRAL STROKES AND ADRENAL HEMORRHAGE ASSOCIATED WITH MIS-A () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1459;
The neuropathology findings suggest SARS-CoV-2 associated vasculitis. Stroke in the context of COVID-19 may have different pathogenetic mechanisms, clinical characteristics and complications that warrant further investigation.
- |||||||||| Aggrastat (tirofiban) / Correvio, Medicure
TIROFIBAN FOR RECENT BILATERAL PIPELINE CAROTID STENTS (BPCS) IN ACUTE INTRACRANIAL HEMORRHAGE (ICH) () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1456;
Description: A 45-year-old female with BPCS secondary to a non-operative traumatic brain injury 3 months prior, on aspirin (ASA) and clopidogrel, presented to the hospital with an acute subdural hemorrhage...Of note, coagulopathy was reversed with 2 separate doses of DDAVP 0.3 mg/kg...Tirofiban was stopped and IVIG as well as dexamethasone was initiated...This case shows utility of tirofiban as a bridging agent in this population that is high risk of both bleeding and thrombosis. It also details an important adverse effect to be aware of associated with the use of tirofiban.
|
